Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/27/2003US6569890 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569888 Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis
05/27/2003US6569887 (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
05/27/2003US6569882 Viricides; enzyme inhibitors
05/27/2003US6569879 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma; benzisoxazole compounds; e.g. ((5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy)acetic acid, methyl ester
05/27/2003US6569878 Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
05/27/2003US6569876 Method and structure for inhibiting activity of serine elastases
05/27/2003US6569871 Substituted imidazole compounds
05/27/2003US6569870 Fluorinated quinolones as antimitotic and antitumor agents
05/27/2003US6569860 Alkoxycarbonylamino-heteroaryl carboxylic acid derivatives useful for treating the disorders of the urinary tract, pain, inflammation, respiratory states, edema formation, hypotensive vascular diseases, pain and allergies
05/27/2003US6569855 Particularly zinc metalloprotease activity for treatment of variety of maladies involving inflammation and/or tissue integrity
05/27/2003US6569853 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
05/27/2003US6569847 Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease
05/27/2003US6569838 Excising the keloid to create a wound, and administering bacterial polysaccharide exotoxin (cm101) to reduce scarring at a site of the wound
05/27/2003US6569666 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
05/27/2003US6569661 Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
05/27/2003US6569642 TNF-Related Apoptosis-Inducing Ligand (TRAIL); isolated DNA probe which hybridizes to nucleic acid of given sequence; use in purifying cells, inhibiting biological activities or as immunogens to produce antibodies
05/27/2003US6569638 Method for screening compounds for the treatment of neoplasia
05/27/2003US6569470 Monoamine oxidase (MAO) inhibitors and uses thereof
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003US6569453 No enteric layers and are suitable for oral administration
05/27/2003US6569434 Vascular endothelial cell growth factor C subunit
05/27/2003US6569429 Isolated polypeptide comprising the amino acid residues 1 to 344 of (SEQ ID NO: 2); systemic lupus erythematosus; pulmonary disease or disorder
05/27/2003US6569416 Compositions containing synthetic soil-extract materials and medicaments based thereon
05/27/2003CA2412624A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurogenerative diseases
05/27/2003CA2412466A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/27/2003CA2268847C Substituted oximes derivatives useful as neurokinin antagonists
05/27/2003CA2268438C Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor
05/27/2003CA2231558C .gamma.-rar antagonist ligand or .alpha.-rar agonist ligand as an apoptosis inhibitor
05/27/2003CA2176229C Improved interferon polymer conjugates
05/27/2003CA2140866C Use of inhibitors of fatty acid synthesis for treating cancer
05/27/2003CA2104297C 4-sulfanimide-quinoline nmda antagonists
05/27/2003CA2031430C Process for refolding recombinantly produced tgf-.beta.-like proteins
05/22/2003WO2003042405A2 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
05/22/2003WO2003042399A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
05/22/2003WO2003042390A1 Mammalian protein phosphatases
05/22/2003WO2003042384A1 Inducer for differentiation of embryo stem cells into ectodermal cells, method of obtaining the same and use thereof
05/22/2003WO2003042381A1 Three-dimensional structure of prostaglandin d synthase and utilization thereof
05/22/2003WO2003042375A1 Stem cells originating in salivary duet epithelial cells and use thereof
05/22/2003WO2003042362A2 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
05/22/2003WO2003042359A2 Histamine receptor h3 polynucleotides
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042344A2 Apo2 ligand/trail formulations
05/22/2003WO2003042247A2 Modified anti-tnf alpha antibody
05/22/2003WO2003042246A2 Inhibitors of the notch signalling pathway for use in the treatment of cancer
05/22/2003WO2003042245A2 Growth hormone variations in humans and their uses
05/22/2003WO2003042226A2 Single nucleotide polymorphisms in gh-1
05/22/2003WO2003042216A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003WO2003042214A2 A2b adenosine receptor antagonists
05/22/2003WO2003042211A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003WO2003042210A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
05/22/2003WO2003042208A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003WO2003042207A1 Thiazolyl substituted triazoles as alk5 inhibitors
05/22/2003WO2003042205A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042204A1 Amine derivative
05/22/2003WO2003042197A1 Oligopeptides and compositions containing them as cathepsin s inhibitors
05/22/2003WO2003042194A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042185A1 Xanthine oxidase inhibitors
05/22/2003WO2003042184A1 Benzimidazol- or indol-aminoacetonitrile derivatives for parasite control
05/22/2003WO2003042181A1 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
05/22/2003WO2003042179A1 Heterocyclic derivatives of glycinamide and their medical use
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042176A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
05/22/2003WO2003042175A1 Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
05/22/2003WO2003042172A2 C-5 modified indazolylpyrrolotriazines
05/22/2003WO2003042164A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003WO2003042160A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003WO2003042113A1 Production of cell suspensions
05/22/2003WO2003041757A2 Catheter injectable depot compositions and uses thereof
05/22/2003WO2003041739A1 Anticaner agents
05/22/2003WO2003041736A2 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003WO2003041729A1 Ptp1b inhibitors and ligands
05/22/2003WO2003041725A2 Regulation of cgmp-specific phosphodiesterase 9a
05/22/2003WO2003041724A1 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
05/22/2003WO2003041715A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003WO2003041711A1 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
05/22/2003WO2003041708A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003WO2003041707A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003WO2003041705A1 Oral dosage form of a sulfonamide prodrug such as parecoxib
05/22/2003WO2003041702A1 Production of pure stereoisomers of tricyclo[5.2.1.02.6]-dec-9-yl xanthogenate and medicaments therefrom
05/22/2003WO2003041701A2 Preparation for improving the action of receptors
05/22/2003WO2003041697A1 Method for treating autoimmune diseases
05/22/2003WO2003041689A1 Biocompatible polymer blends and uses thereof
05/22/2003WO2003041685A1 Injectable depot composition
05/22/2003WO2003041683A2 Orodispersible tablets containing fexofenadine
05/22/2003WO2003041679A2 Product containing a red alga extract of the genus porphyra and uses thereof for protecting cells
05/22/2003WO2003041669A1 A composition for promoting hair growth
05/22/2003WO2003041660A2 Solubilized topoisomerase poisons
05/22/2003WO2003041650A2 Modulation of lir function to treat rheumatoid arthritis
05/22/2003WO2003041649A2 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003WO2003020732A3 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors.
05/22/2003WO2003007883A3 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
05/22/2003WO2002100353A3 Cd10-activated prodrug compounds
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002098438A9 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
05/22/2003WO2002083120A3 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
05/22/2003WO2002076390A3 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
05/22/2003WO2002058737A3 Multivalent meningococcal polysaccharide-protein conjugate vaccine
1 ... 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 ... 1564